The present disclosure relates to a group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein. Composition matters and methods of uses are within the scope of this disclosure.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

The present disclosure relates to a group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein. Composition matters and methods of uses are within the scope of this disclosure.

A Covid-19 susceptibility testing device including a receiving chamber configured to receive a human bodily fluid and a reaction medium configured to indicate Covid-19 susceptibility when concentration of an analyte exceeds a predetermined threshold in the human bodily fluid.

A group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein.

The present disclosure relates to a group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein. Composition matters and methods of uses are within the scope of this disclosure.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

A group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein.

Provided are peptide-based nanostructures, as well as diagnostic and therapeutic methods using same.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.